Inclusion Criteria:
- Subjects in the SANS-UUI Phase I or Phase II study
Primary Investigator
Prospective, multi-center, single-arm, post-approval study is designed to assess the long-term safety and efficacy data of the Neuspera Sacral Neuromodulation (SNM) System following commercial approval of the Neuspera SNM System.
Participants in this study received intervention/implanted in Phase I or Phase II of the Neuspera SANS_UUI (NSM-004) Study.
The Neuspera SNM System received FDA PMA approval for the treatment of urinary urge incontinence in subjects who have failed, could not tolerate, or were not a candidate for more conservative treatment. The study will serve as the Post Approval Study (PAS) requirement of the PMA Approval.
This post approval study (PAS) is designed to assess the long-term safety and effectiveness data out to 72 months post-implant, in consenting subjects implanted in Phase I or Phase II study.
You may be eligible for this study if you meet the following criteria:
Inclusion Criteria:
The purpose of this study is to investigate the long-term safety and effectiveness of an investigational sacral neuromodulation system for patients experiencing urinary urgency incontinence. Urinary urgency incontinence is a condition where there is a sudden need to urinate that is difficult to control, leading to involuntary leakage of urine.
Participants in the study will undergo procedures to evaluate the performance of the sacral neuromodulation system. This involves regular assessments to monitor the system's safety and how well it works in managing urinary urgency incontinence symptoms.
This study is accepting only persons who receive care at a certain clinic or doctor or who are part of an invited group. Questions about this study can be directed to the study team listed in the description or contact your doctor to see if you are eligible.
or